Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial

BACKGROUND: Rituximab is effective as therapy for induction of remission in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and subsequent relapse rates are high, especially in patients with a history of relapse. There is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gopaluni, Seerapani, Smith, Rona M., Lewin, Michelle, McAlear, Carol A., Mynard, Kim, Jones, Rachel B., Specks, Ulrich, Merkel, Peter A., Jayne, David R. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341185/
https://www.ncbi.nlm.nih.gov/pubmed/28270229
http://dx.doi.org/10.1186/s13063-017-1857-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341185/
https://www.ncbi.nlm.nih.gov/pubmed/28270229
http://dx.doi.org/10.1186/s13063-017-1857-z

Ejemplares similares